Despite a couple of notable 'firsts' for European public biotech financing, biotech's COVID-19 bubble may be...
OPINION
Experts Point of View
Medicines for rare and paediatric diseases have been successfully enabled through the EU’s incentives...
The past two years could be called the years of messenger RNA (mRNA) technology, with two major biotech...
The COVID-19 pandemic has demonstrated how vulnerable human beings and societies are to a new infectious...
New entrants and variants will be main drivers of the COVID-19 vaccine market as supply gradually begins
to...
The Commission study on Novel Genomic Techniques (NGTs) underlines that plants resulting from NGTs have the...
Share
